A Multicenter, Prospective Study Assessing the Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir (G/P) in Patients with Chronic Hepatitis C Virus Infection within the German Hepatitis C-Registry (DHC-R)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glecaprevir/pibrentasvir (Primary)
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

13 Nov 2018 Results of a retrospective analysis assessing Drug-Drug Interaction Potential of Glecaprevir/ Pibrentasvir (n=19,042) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
07 Oct 2018 Results presented at the IDWeek 2018
10 Jul 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight